Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III nemolizumab in Japanese atopic dermatitis with moderate to severe pruritus
jRCT2080223684Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Nemolizumab with Placebo (2 arms). Primary endpoints: Percent change from baseline in pruritus VAS at Week 16 and Percent change from baseline in EASI at Week 16. Started Oct 2017; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080223684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223684.